biostudies-literatureUnknown55(6)Gokcay Canpolat A<h4>Background/aim</h4>To describe Graves' Disease (GD) associated with COVID-19 infection (COVID) or its vaccines (VAC) and to compare the clinical presentations, laboratory parameters, and short-term clinical course of the disease among different etiology groups (COVID, VAC, and GD control).<h4>Materials and methods</h4>Included in this multicenter matched case-control, retrospective cohort study were 239 patients with newly diagnosed (n = 196) or recurrent GD (n = 43) associated with COVID (n = 79) or VAC (n = 160). Each case was matched (1:1) with a control who had been diagnosed with GD prior to COVID.<h4>Results</h4>The median age of the entire group was 42 years (female:male = 137:102). Both the COVID (4.6-fold) and VAC (4.1-fold) groups demonstrated higher TSH receptor antibody (TRTurkish journal of medical sciences1381-1393https://www.ebi.ac.uk/biostudies/studies/S-EPMC12779019biostudies-literatureClinical characteristics of Graves' disease following COVID-19 infection or vaccination: a multicenter case-control study.PMC12779019Kara BBalos Toruner FAydemir MCansu GBYalcin MPolat SBAlagol FOmma TElhan AHYazici DAlphan Uc ZGokcay Canpolat ABostan HOguz ABatman AFaki SAsik MUcan BEvren BUgur KKubat Uzum AMutlu UGurlek AOk AMSahin MInce NCesur MIliksu Gozu HYildiz BOKarakilic ECakir BCakal EYilmaz MErdogan MFAkcay SAgbaht KErturk MSYorulmaz GSaygili ESSah Unal TAnil CUnal MCErsoy RKayhan YTopaloglu OfalseClinical characteristics of Graves' disease following COVID-19 infection or vaccination: a multicenter case-control study.<h4>Background/aim</h4>To describe Graves' Disease (GD) associated with COVID-19 infection (COVID) or its vaccines (VAC) and to compare the clinical presentations, laboratory parameters, and short-term clinical course of the disease among different etiology groups (COVID, VAC, and GD control).<h4>Materials and methods</h4>Included in this multicenter matched case-control, retrospective cohort study were 239 patients with newly diagnosed (n = 196) or recurrent GD (n = 43) associated with COVID (n = 79) or VAC (n = 160). Each case was matched (1:1) with a control who had been diagnosed with GD prior to COVID.<h4>Results</h4>The median age of the entire group was 42 years (female:male = 137:102). Both the COVID (4.6-fold) and VAC (4.1-fold) groups demonstrated higher TSH receptor antibody (TR2025-01-01T00:00:00Z20252026-06-06T12:45:46.659Z2026-05-30T03:11:38.411ZS-EPMC127790194150994410.55730/1300-0144.6096